Repligen
RGEN
#1868
Rank
S$14.13 B
Marketcap
S$222.64
Share price
6.13%
Change (1 day)
15.40%
Change (1 year)
Categories

Repligen (RGEN) - Total debt

Total debt on the balance sheet as of June 2026 : S$0.88 Billion

According to Repligen 's latest financial reports the company's total debt is S$0.88 Billion. A companyโ€™s total debt is the sum of all current and non-current debts.

Repligen - Total debt on balance sheet (from 2004 to 2026)

Total debt by year

Year Total debt Change
2025-12-31S$0.88 B-5.04%
2024-12-31S$0.93 B-0.77%
2023-12-31S$0.94 B65.79%
2022-12-31S$0.56 B14.58%
2021-12-31S$0.49 B35.82%
2020-12-31S$0.36 B2.64%
2019-12-31S$0.35 B151.1%
2018-12-31S$0.14 B6.5%
2017-12-31S$0.13 B-3.73%
2016-12-31S$0.13 B
2005-03-31S$0.19 M38.97%
2004-03-31S$0.14 M

Total debt for similar companies or competitors

Company Total debt/th> differencediff. Country
Pfizer
PFE
S$80.91 B 9,046.06%๐Ÿ‡บ๐Ÿ‡ธ USA
Thermo Fisher Scientific
TMO
S$54.47 B 6,058.11%๐Ÿ‡บ๐Ÿ‡ธ USA
General Electric
GE
S$24.52 B 2,672.59%๐Ÿ‡บ๐Ÿ‡ธ USA
Bristol-Myers Squibb
BMY
S$57.68 B 6,420.52%๐Ÿ‡บ๐Ÿ‡ธ USA
Sangamo Therapeutics
SGMO
S$24.75 M-97.20%๐Ÿ‡บ๐Ÿ‡ธ USA
Novavax
NVAX
S$0.38 B-56.97%๐Ÿ‡บ๐Ÿ‡ธ USA
Neurocrine Biosciences
NBIX
S$0.51 B-41.85%๐Ÿ‡บ๐Ÿ‡ธ USA
Bio-Techne
TECH
S$0.37 B-58.16%๐Ÿ‡บ๐Ÿ‡ธ USA
BioMarin Pharmaceutical
BMRN
S$5.38 B 508.18%๐Ÿ‡บ๐Ÿ‡ธ USA
Charles River Laboratories
CRL
S$3.87 B 338.20%๐Ÿ‡บ๐Ÿ‡ธ USA